Course of EYS-associated retinitis pigmentosa in adults from Russia and former CIS

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a four-year observational natural history program enrolling adults with pathogenic EYS variants to collect functional, structural, and patient-reported outcomes. Participants will undergo genetic confirmation (whole exome/genome sequencing where needed), retinal imaging, visual field testing, electrophysiology, visual acuity measures, and standardized questionnaires at planned visits. Data will be analyzed for progression rates, left-right eye symmetry, genotype-phenotype correlations, and environmental or comorbidity risk factors for decline. The primary aim is to identify sensitive, reliable outcome measures and well-defined subgroups to enable future multicenter therapeutic trials for EYS-related retinal degeneration.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Willing to participate in the study and able to communicate consent during the consent process
2. Ability to return for all study visits over 48 months
3. Age ≥ 18 years
4. Must meet one of the Genetic Screening Criteria, defined below:

Screening Group A: At least 2 disease-causing variants in the EYS gene which are homozygous or heterozygous in trans, based on a report from a clinically-certified lab (or a report from a research lab that has been pre-approved by the Study Committee) Screening Group B: Only 1 disease-causing variant in the EYS gene, based on a report from a clinically-certified lab (or a report from a research lab which has been pre-approved by the Study Committee) Screening Group C: At least 2 disease-causing variants in the EYS gene which are unknown phase, based on a report from a clinically-certified lab (or a report from a research lab which has been pre-approved by the Study Committee) Note pertaining to all Screening Groups: if a participant has a variant(s) of unknown significance, he/she would still qualify as long as there is at least 1 disease-causing variant(s) on the EYS gene.

Ocular Inclusion Criteria:

Both eyes must meet all of the following:

1. Clinical diagnosis of retinal dystrophy
2. Clear ocular media and adequate pupil dilation to permit good quality photographic imaging

Exclusion Criteria:

1. Mutations in genes that cause autosomal dominant retinitis pigmentosa (ADRP), X-linked retinitis pigmentosa (RP), or presence of biallelic mutations in autosomal recessive RP/retinal dystrophy genes other than EYS.
2. Expected to enter experimental treatment trial at any time during this study
3. History of more than 1 year of cumulative treatment, at any time, with an agent associated with pigmentary retinopathy (including hydroxychloroquine, chloroquine, thioridazine, and deferoxamine)

Ocular exclusion Criteria:

If either eye has any of the following, the participant is not eligible:

* Current vitreous hemorrhage
* Current or any history of rhegmatogenous retinal detachment
* Current or any history of (e.g., prior to cataract or refractive surgery) spherical equivalent of the refractive error worse than -8 Diopters of myopia
* History of intraocular surgery (e.g., cataract surgery, vitrectomy, penetrating keratoplasty, or LASIK) within the last 3 months
* Current or any history of confirmed diagnosis of glaucoma (e.g., based on glaucomatous visual functions changes or nerve changes, or history of glaucoma filtering surgery)
* Current or any history of retinal vascular occlusion or proliferative diabetic retinopathy
* History or current evidence of ocular disease that, in the opinion of the investigator, may confound assessment of visual function
* History or evidence of active treatment for retinitis pigmentosa that could affect the progression of retinal degeneration, including:
* Any use of ocular stem cell or gene therapy
* Treatment with an ophthalmic oligonucleotide within the last 9 months (last treatment date is less than 9 months prior to Screening Visit date)
* Treatment with any other product within five times the expected half-life of the product (time from last treatment date to Screening Visit date is at least 5 times the half-life of the given product)

Where it's running

• Oftalmic Clinical Research Center
  Moscow, Russia Recruiting

Study contacts

• Principal investigator: Marianna Weener, MD, PhD — Oftalmic
• Study coordinator: Olga Luneva
• Email: info@oftalmic.com
• Phone: +7 9629412912

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using stem cells from umbilical cords to treat non-arteritic ischemic optic neuropathy

  This study is testing if using stem cells from umbilical cords can help people with non-arteritic ischemic optic neuropathy improve their vision and overall eye health.

  Recruiting at 2 sites Phase 1 The Foundation for Orthopaedics and Regenerative Medicine · Naples, Florida and 1 other locations · NCT05147701

• ETHY-001 safety and activity in Thyroid Eye Disease (TED)

  This study tests ETHY-001 versus placebo to see if it is safe, tolerable, and shows activity in people with thyroid eye disease.

  Recruiting at 2 sites Phase 1 Ethyreal Bio, Inc. · Orland Park, Illinois and 2 other locations · NCT07885605

• Functional visual field and navigation testing for moderate-to-profound inherited retinal disease

  This project will test whether functional visual field and navigation tests can measure real-world vision and mobility in people with moderate-to-profound inherited retinal diseases.

  Recruiting Ray Therapeutics, Inc. · Irvine, California · NCT07502664

• Autologous Serum Tears with Hyaluronate vs Standard Serum Tears for Moderate-to-Severe Dry Eye

  This study tests whether adding sodium hyaluronate to autologous serum eye drops provides better relief for adults with moderate-to-severe dry eye in one eye, compared with the standard serum drops in the other eye.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT07413172

• OCT-980 oral treatment for rhodopsin-associated autosomal dominant retinitis pigmentosa

  This program will test whether the oral drug OCT-980 is safe, well tolerated, and shows signs of benefit in adults with RHO-associated autosomal dominant retinitis pigmentosa and in healthy volunteers.

  Recruiting at 2 sites Phase 1/2 Octant, Inc. · Portland, Oregon and 1 other locations · NCT07408232

• Two approaches to repeat eyelid surgery for post-operative trichiasis

  This project will try whether the newer Bevel-Rotate Advancement Procedure (B-RAP) or the standard Bilamellar Tarsal Rotation (BLTR) gives better results for people in Tanzania who need repeat surgery for post-operative trachomatous trichiasis.

  Recruiting at 2 sites University of North Carolina, Chapel Hill · Chapel Hill, North Carolina and 1 other locations · NCT07322302

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.